4503
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Astellas Pharma Inc. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The group operates as a single business segment focused on pharmaceuticals, with no distinct reportable segments. Key subsidiaries include Astellas Pharma Global Development Inc., Astellas Institute for Regenerative Medicine, and Astellas Gene Therapies Inc. for research and development; Astellas Ireland Co., Ltd. and Astellas Pharma (China) Co., Ltd. for manufacturing; and Astellas Pharma US, Inc., Astellas Pharma GmbH, Beijing Astellas Pharmaceutical Co., Ltd., Astellas Pharma S.A.S, Astellas Pharma S.A., and Korea Astellas Pharma Co., Ltd. for sales and distribution. The company supplies raw materials and finished products to its regional affiliates and serves markets in the United States, Germany, China, France, Spain, and South Korea.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage astellas.com
Sector Healthcare IR page astellas.com/en
Tags
pharmaceuticals, gene therapy, regenerative medicine, drug development, manufacturing, distribution, Astellas Pharma Global Development Inc., Astellas Institute for Regenerative Medicine, Astellas Gene Therapies Inc., Astellas Ireland Co. Ltd., Astellas Pharma (China) Co. Ltd., Astellas Pharma US Inc., Astellas Pharma GmbH, Beijing Astellas Pharmaceutical Co. Ltd., Astellas Pharma S.A.S, Astellas Pharma S.A., Korea Astellas Pharma Co. Ltd.
Press page astellas.com/jp/media/news

Metrics

Valuation  
Market cap ¥ 4.151T
Market cap (USD) $ 25.946B
P/E 10.66
PEG 0.25
P/BV 2.09
P/S 1.74
P/OCF 7.58
P/FCF 9.51
Dividend yield 3.4%
Turnover / mcap —
Returns  
ROE 17.4%
ROI 12.2%
ROIC 12.4%
Profit margin 13.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 43.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 61.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 2.139T 1.912T 1.604T 1.519T 1.296T 1.25T 1.301T 1.306T 1.3T 1.312T 1.373T 1.247T 1.165T 1.006T
Net profit 291.535B 50.747B 17.045B 98.714B 124.086B 120.589B 195.411B 222.265B 164.679B 218.701B 193.687B 135.856B 92.434B 82.851B
Free cash flow 475.543B 137.182B 89.978B 291.326B 180.996B 229.402B 144.11B 206.502B — — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 2.525K 1.446K 1.645K 1.882K 1.911K 1.703K 1.667K 1.656K 1.611K 1.463K 1.498K 1.968K 1.225K 1.012K
Price performance 12m 0.75 -0.12 -0.13 -0.02 0.12 0.02 0.01 0.03 0.1 -0.02 -0.24 0.61 0.21 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Borrowings, current (JPY) — — — — — — 75B 472B 267B 246B
Borrowings, non-current (JPY) — — — — — — 50B 448B 565B 320B
Cash and deposits (JPY) 341B 332B 311B 318B 326B 316B 377B 336B 188B 282B
Intangible assets (JPY) — 417B 430B 739B 651B 623B 562B 1.45T 1.12T 997B
Right-of-use assets (JPY) — — — 80.8B 67.2B 60.8B 61.8B 65.2B 82.5B 76.9B
Net debt (borrowings + leases - cash) (JPY) — — — — — — -252B 584B 643B 284B
Cash flow detail
Operating cash flow (JPY) 236B 313B 259B 222B 307B 257B 328B 172B 195B 560B
Purchases of property, plant and equipment (JPY) — -25.1B -25.2B -41.3B -31.4B -30.7B -36.4B -38.1B -37B -57.7B
Purchases of intangible assets (JPY) — -15.2B -26.9B -36.6B -46.1B -45.7B -52.1B -44.4B -20.3B -26.9B
Change in inventories (cash effect) (JPY) — 37.8B -5.48B -6.04B -2.32B 24.1B -7.09B -60B -50.2B -16.2B
Dividends paid (cash effect) (JPY) — -71.6B -72.1B -73.5B -76.2B -85.2B -100B -117B -129B -136B
Share buybacks (cash effect) (JPY) — -131B -160B -52.9B -9.16B -50.7B -60.6B -10.7B -6.96B -730M
Income taxes paid (cash effect) (JPY) — -65B -69.9B -48B -17.9B -42.1B -69.5B -38.1B -85.5B -98.6B
Free cash flow (OCF - PPE - intangibles) (JPY) — 272B 207B 144B 229B 181B 239B 90B 137B 476B
Income detail
Research and development expense (JPY) — 221B 209B 224B 225B 246B 276B 294B 328B 315B
↳ 5y CAGR +4.6% +7.1% +7.9% +7.0%
Total comprehensive income (JPY) — 199B 222B 157B 181B 208B 205B 206B 48.9B 449B
Comprehensive income to owners (JPY) 175B 199B 222B 157B 181B 208B 205B 206B 48.9B 449B
Reported Jun 19, 2017 Jun 18, 2019 Jun 18, 2019 Jun 18, 2020 Jun 18, 2021 Jun 20, 2022 Aug 7, 2023 Jun 20, 2024 Jun 16, 2025 Jun 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Astellas Pharma Inc. (ticker 4503), listed in Japan.

ETFs Holding Astellas Pharma Inc.

ETF Weight in ETF Shares Market value As of
IVAL 2.29% 293,860 $ 5.03M Nov 18, 2026
BINV 1.90% 696,900 $ 9.322M Jun 30, 2026
DTAN 0.96% 12,200 $ 209.018K Nov 17, 2026
DSTX 0.93% 32,900 $ 440.286K Jun 30, 2026
VDI 0.69% 8,100 $ 112.103K Jul 31, 2026
DWMF 0.61% 15,600 $ 208.768K Jun 30, 2026
DIHP 0.45% 1,777,700 $ 29.773M Nov 12, 2026
AVIV 0.37% 453,200 $ 7.672M Nov 16, 2026
AVSD 0.30% 66,400 $ 1.124M Nov 16, 2026
DXIV 0.30% 42,500 $ 711.789K Nov 12, 2026
DFSI 0.21% 148,100 $ 2.48M Nov 12, 2026
IVSI 0.18% 1,040 $ 13.912K Jun 30, 2026
AVDE 0.17% 2,012,200 $ 34.063M Nov 16, 2026
NTSI 0.15% 56,400 $ 754.776K Jun 30, 2026
DFIC 0.14% 1,327,300 $ 22.23M Nov 12, 2026
DFAI 0.14% 1,531,254 $ 25.645M Nov 12, 2026
FLSP 0.13% 88,600 $ 1.186M Jun 30, 2026
DFAX 0.09% 646,300 $ 10.824M Nov 12, 2026
JSTC 0.03% 5,955 $ 102.4K Nov 17, 2026